Healthcare Providers and Services
Company Overview of Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. provides cancer treatment and research services for adults and children in the United States. It offers adult treatment and care services for blood, breast, cutaneous/skin, gastrointestinal, genitourinary, gynecological, head and neck, hematology, melanoma, neuro-oncology, sarcoma, and thoracic cancer; and cancer genetics and prevention services. The company also provides treatment and care for children with cancer, such as blood diseases, bone and soft tissue tumors, brain tumors, histiocytosis, Hodgkin lymphoma, kidney tumors, leukemia, neuroblastoma, non-Hodgkin lymphoma, and rare tumors program. In addition, it offers training in cancer treatment and re...
450 Brookline Avenue
Boston, MA 02215-5450
Founded in 1947
Key Executives for Dana-Farber Cancer Institute, Inc.
Chief Executive Officer and President
Chief Financial Officer and Assistant Treasurer
Chief Operating Officer and Executive Vice President
Senior Vice President and General Counsel
Senior Vice President for Research
Compensation as of Fiscal Year 2014.
Dana-Farber Cancer Institute, Inc. Key Developments
Johnson & Johnson Innovation Announces Immuno-Oncology Lung Cancer Collaboration with the Dana-Farber Cancer Institute's Belfer Institute for Applied Cancer Science
Jun 24 14
Johnson & Johnson Innovation announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Through the collaboration, Janssen scientists will work with the research team at Dana-Farber's Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen's lung cancer discovery pipeline. Utilizing the Belfer Institute's proprietary immuno-oncology lung platform and lung cancer disease expertise, the research teams will also seek to identify rational immuno-oncology drug combination strategies and biomarkers, and to characterize mechanisms of resistance. The collaboration will also identify and validate novel targets for lung cancers. Lung cancer is one of three focus areas for Janssen Oncology based on its high unmet need.
Dana-Farber Cancer Institute, Inc. Presents at 7th Annual State of the Market Conference, Jun-19-2014 10:45 AM
Jun 16 14
Dana-Farber Cancer Institute, Inc. Presents at 7th Annual State of the Market Conference, Jun-19-2014 10:45 AM. Venue: The Plaza Hotel, New Y ork, New York, United States. Speakers: Edward J. Benz, Chief Executive Officer and President.
TrovaGene, Inc. Announces Clinical Collaboration with Dana-Farber Cancer Institute
Jun 16 14
Trovagene, Inc. announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients. Under the agreement, urine samples will be collected from patients with locally advanced or metastatic melanoma known to harbor driver oncogene mutations. A Dana-Farber oncology team, led by Jason Luke, M.D., will conduct clinical studies designed to monitor oncogene mutations in study subjects based on urinary cell-free DNA as an analytical specimen. Studies will be designed to collect data regarding the clinical status of patients, treatment effect, and long-term outcomes of therapy using Trovagene's non-invasive molecular diagnostic technology. Trovagene is engaged in numerous collaborations designed to demonstrate the clinical utility of its precision cancer monitoring platform for the detection of mutational status in cancer patients, and the assessment of tumor dynamics and treatment response over time. To date, the company has processed over 1,000 patient samples under its collaborations, and is focused on developing the clinical evidence to support broad market adoption of its technology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|